Funded globally by the Movember charity and led by Dr Nicolas Hart from Edith Cowan University in Perth, the INTERVAL-GAP4 study is a multinational, multi-centre and multidisciplinary RCT with 24 months of supervised tapered to self-managed exercise with behavioural and psychosocial support, compared with self-directed exercise with psychosocial support alone, in men with metastatic castrate-resistant prostate cancer (mCRPC).
The study will determine the efficacy of an individually tailored, progressive and autoregulated aerobic and resistance exercise programme, supervised by accredited exercise physiologists (or equivalent) in addition to usual medical care, in parallel with a health economics analysis to assess the health benefits, additional costs and potential savings of including exercise therapy as standard of care for men with mCRPC.
Given the international and multi-centre approach, and with a cohort of 866 patients, the Physitrack platform was chosen to not only deliver exercise programs to cohorts world-wide, but also allow researchers to collect and analyse outcomes data remotely in real-time.
Marijn Kortekaas, Partner and GM Asia Pacific with Physitrack: “It’s great exciting to see Dr Hart and his team use Physitrack to its full potential, driven by the diverse locations patients are based. As patients log their progress via the free PhysiApp patient app, the research team can analyse the outcomes data in minute detail. For our patient engagement and Telehealth platform to be used for such a great cause is very rewarding."
For more details about the RCT see http://bmjopen.bmj.com/content/8/5/e022899